Autres langues INmune Bio, Inc.

Actions

INMB

US45782T1051

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
11,2 ^USD	-3,20%		-4,84%	-0,53%

30/04	INmune Bio, Inc. fait une mise à jour sur deux patients de l'étude de phase 1b sur la maladie d'Alzheimer	CI
29/04	INmune Bio Inc. Achève la première cohorte et entame la deuxième cohorte de l'étude de phase 1/2 de la thérapie par cellules tueuses naturelles INKmune ? Natural Killer Cell Therapy chez des patients atteints d'un cancer de la prostate métastatique résistant à la castration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years	30/04
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial	30/04
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	29/04
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	29/04
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	25/04
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	25/04
INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling and Development of Novel Immunogenicity Assay	24/04
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	23/04
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	23/04
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	23/04
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering	22/04
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08/04
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08/04
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	08/04
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update	28/03
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28	26/03
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy	13/03
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy	13/03
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues INmune Bio, Inc.

Actions

INMB

US45782T1051

Autres langues

Filtres